Martine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $287.22, for a total transaction of $1,033,992.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $37,338.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

United Therapeutics Stock Performance

Shares of UTHR opened at $306.04 on Wednesday. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $306.78. The firm has a fifty day simple moving average of $260.62 and a 200 day simple moving average of $239.50. The stock has a market capitalization of $13.58 billion, a price-to-earnings ratio of 14.47, a PEG ratio of 4.29 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, beating the consensus estimate of $5.63 by $0.54. The company had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. United Therapeutics’s revenue for the quarter was up 33.7% compared to the same quarter last year. During the same quarter last year, the company earned $4.86 EPS. Research analysts forecast that United Therapeutics Co. will post 24.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. HC Wainwright restated a “buy” rating and issued a $300.00 price target on shares of United Therapeutics in a report on Thursday, May 2nd. The Goldman Sachs Group raised their target price on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Oppenheimer upped their price target on shares of United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a report on Thursday, May 2nd. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, June 12th. Finally, Wells Fargo & Company upped their target price on shares of United Therapeutics from $325.00 to $350.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 12th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Buy” and a consensus target price of $312.22.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. J.P. Morgan Private Wealth Advisors LLC increased its holdings in United Therapeutics by 6.1% during the third quarter. J.P. Morgan Private Wealth Advisors LLC now owns 1,275 shares of the biotechnology company’s stock worth $288,000 after buying an additional 73 shares during the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of United Therapeutics by 17.0% in the 3rd quarter. Janney Montgomery Scott LLC now owns 8,809 shares of the biotechnology company’s stock valued at $1,990,000 after purchasing an additional 1,279 shares during the period. Pathstone Family Office LLC bought a new stake in shares of United Therapeutics in the 3rd quarter valued at about $369,000. HighTower Advisors LLC lifted its stake in United Therapeutics by 26.8% in the 3rd quarter. HighTower Advisors LLC now owns 4,239 shares of the biotechnology company’s stock valued at $956,000 after purchasing an additional 895 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in United Therapeutics by 10.7% during the third quarter. PNC Financial Services Group Inc. now owns 2,472 shares of the biotechnology company’s stock worth $558,000 after purchasing an additional 239 shares during the period. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.